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AbstrACt
Introduction End- stage kidney disease (ESKD) is a 
major public health problem affecting more than 2 million 
people worldwide. It is one of the most severe chronic 
non- communicable diseases. Haemodialysis (HD) is the 
most common therapeutic option but is also associated 
with a risk of cardiovascular events, hospitalisation 
and suboptimal quality of life. Over the past decades, 
haemodiafiltration (HDF) has become available. Although 
high- dose HDF has shown some promising survival 
advantage compared to conventional HD, the evidence 
remains controversial. A Cochrane systematic review 
found, in low- quality trials, with various convective forms 
of dialysis, a reduction in cardiovascular, but not all- cause 
mortality and the effects on non- fatal cardiovascular 
events and hospitalisation were uncertain. In contrast, an 
individual patient data analysis suggested that high- dose 
HDF reduced both all- cause and cardiovascular mortality 
compared to HD. In view of these discrepant results, a 
definitive trial is required to determine whether high- dose 
HDF is preferable to high- flux HD. The comparison of 
high- dose HDF with high- flux HD (CONVINCE) study will 
assess the benefits and harms of high- dose HDF versus a 
conventional high- flux HD in adults with ESKD.
Methods and analysis This international, prospective, 
open label, randomised controlled trial aims to recruit 
1800 ESKD adults treated with HD in nine European 
countries. Patients will be randomised 1:1 to high- dose 
HDF versus continuation of conventional high- flux HD. 
The primary outcome will be all- cause mortality at 
3 years’ follow- up. Secondary outcomes will include 
cause- specific mortality, cardiovascular events, all- cause 
and infection- related hospitalisations, patient- reported 
outcomes (eg, health- related quality of life) and cost- 
effectiveness.
Ethics and dissemination The CONVINCE study will 
address the question of benefits and harms of high- dose 
HDF compared to high- flux HD for kidney replacement 
therapy in patients with ESKD with a focus on survival, 
patient perspectives and cost- effectiveness.
trial registration number Netherlands National Trial 
Register (NTR 7138).
IntroduCtIon
End- stage kidney disease (ESKD) is a major 
public health problem, affecting more than 2 
million people requiring kidney replacement 
therapy in 2015,1 and the global prevalence 
of kidney replacement therapy is expected 
to double by the year 2025, reaching 4.9 
million people.2 ESKD is one of the most 
severe chronic non- communicable diseases 
worldwide associated with approximately 
10%–20% mortality after 1 year.3 The 5- year 
mortality rate is above that of some of the 
more common solid organ malignancies, 
including regional breast cancer, regional 
strengths and limitations of this study
 ► This is the largest randomised trial to assess the 
efficacy and safety of high- dose haemodiafiltration 
versus continuation of conventional high- flux hae-
modialysis in patients with end- stage kidney dis-
ease (ESKD).
 ► Information will be collected about patient- reported 
outcomes, particularly health- related quality of life.
 ► A cost- effectiveness analysis for the two treatment 
modalities will be performed.
 ► Information about co- medications, given that pa-
tients with ESKD have often comorbidities, will be 
collected during follow- up.
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colon cancer and kidney cancer.4 5 Kidney replacement 
therapy is generally required when residual kidney func-
tion falls below 10% of the normal value and therapeutic 
options include haemodialysis (HD), peritoneal dial-
ysis and kidney transplantation. Regenerative medicine, 
to develop an implantable kidney, is still in the experi-
mental phase and access to kidney transplantation varies 
between countries. Even in those countries with an active 
transplant programme, only around 20% of the dialysis 
population are listed for transplantation.6 Worldwide, 
HD treatment is the standard of care for the vast majority 
of patients with ESKD.1 7 However, the risk for fatal and 
non- fatal cardiovascular events, infections, hospitalisation 
and reduced quality of life is high among patients treated 
with HD.7 8 Given the high prevalence and high mortality 
rates, improvements in the currently available standard 
HD care are needed.
High- flux HD is defined as HD using high- flux dial-
ysis membranes and bicarbonate- based dialysate. Over 
the past decades, haemodiafiltration (HDF),9 an alter-
native to standard HD, has become available. By adding 
convective clearance HDF removes middle and large 
uraemic compounds that accumulate due to kidney 
failure more effectively than standard high- flux HD. 
Greater convective exchange increases the clearance of 
uraemic toxins.10 HDF might also improve survival by 
increasing the removal of middle- sized uraemic toxins, 
reducing oxidative stress11 12 and improving intradialytic 
cardiovascular stability.13 A recent individual patient- level 
data meta- analysis, including 2753 patients14 15 has shown 
that, during a median follow- up of 2.5 years, compared to 
the standard HD, a high- dose HDF (convection volume 
>23 L/session) reduced the risk of all- cause mortality 
by approximately 22%, and of cardiovascular disease 
mortality by 31%,14 the latter mostly due to reduction 
in coronary heart disease death.16 However, a previous 
Cochrane systematic review reported that convective 
dialysis therapies appeared to reduce cardiovascular, but 
not all- cause, mortality and had uncertain effects on non- 
fatal cardiovascular events and hospitalisation compared 
to HD. The quality of evidence was considered low due 
to methodological limitations and poor reporting of the 
primary studies. In addition, the majority of trials were 
not specifically designed to assess the effects of various 
convection volumes. Thus, patients were not randomised 
to different targets of convective volumes and were not 
equally likely to achieve a specific convective volume (ie, 
healthier patients were more likely to achieve a higher 
convection volume).15 17–19 Furthermore, there was 
remarkable heterogeneity in the dialysis interventions 
across studies, including differences in convective modali-
ties ranging from haemofiltration, HDF with bagged solu-
tions, and online HDF. When HDF was first introduced, 
small volume convective exchanges were performed 
with sterile bagged fluid replacement,20 and it was only 
more recently, following technical advances in dialysis 
machines21 and production of online ultra- pure dialysis 
water,9 that higher volume convective exchanges were 
possible.10 As such, depending on which studies were 
considered, published meta- analyses report either a bene-
ficial effect for HDF or no benefit compared to conven-
tional high- flux HD.19 22 23
We report on the design of the CONVINCE study, a 
randomised controlled trial that evaluates the benefits 
and harms of a high- dose HDF versus a conventional 
high- flux HD treatment in adults with ESKD.
study objectives
Based on previous evidence, we hypothesise that high- dose 
HDF will significantly decrease mortality risk compared 
to conventional high- flux HD treatment in adults with 
ESKD. The objectives of our study are:
1. To evaluate the comparative efficacy of high- dose HDF 
and high- flux HD on all- cause and cause- specific death, 
fatal and non- fatal cardiovascular events, all- cause and 
cause- specific hospitalisations.
2. To evaluate the effect of high- dose HDF versus high- 
flux HD on patient- reported outcomes (PROs), partic-
ularly health- related quality of life.




Eligible patients will be adults with ESKD treated with 
high- flux HD compliant with the inclusion and exclusion 
criteria outlined in table 1. Participants will be recruited 
in up to nine European countries. As of June 2019, we are 
active in France, Germany, Hungary, Poland, Portugal, 
Romania, Spain, The Netherlands and the United 
Kingdom. Around 70 sites will participate, including both 
academic and hospital based- dialysis centres, and private 
dialysis providers (Fresenius Medical Care, B. Braun 
Avitum and Diaverum).
study design
The CONVINCE study is an international, prospective, 
randomised, controlled trial. Allocation to high- flux HD 
and high- dose HDF will be concealed by central rando-
misation, with a 1:1 ratio. A block randomisation scheme, 
stratified by centre, will be conducted.
study intervention
The experimental intervention will be a high- dose HDF 
with online production of substitution fluid and ultra-
pure dialysis fluid. Substitution fluid should be infused 
in postdilution mode.8 In case of different substitution 
modality (pre, mid or mixed dilution) a correction 
factor (2 to 1.5 times higher than in post dilution mode 
respectively) will be applied to match the performance 
as detailed in online supplementary appendix 1. High- 
dose HDF is defined as a convection volume of ≥23 L 
(range ±1 L). Previous studies have shown that it is also 
possible to achieve these convection volumes in older 
patients with comorbidities.24 25 In cases where the target 
convection volume (≥23 L/ session; range ±1 L) is not 
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Table 1 Inclusion and exclusion criteria for enrolment in CONVINCE
Inclusion criteria A participant must meet ALL of the following criteria in order to participate:
1. Signed and dated written Informed Consent Form obtained from the participant or his/her guardian or in 
accordance with local regulations.
2. Aged ≥18 years.
3. Diagnosed with ESKD.
4. On HD treatment for ≥3 months.
5. Likely to achieve high- dose HDF (≥23 L, in postdilution mode), according to the protocol.
6. Willing to have a dialysis session with duration of ≥4 hours, three times a week.
7. Understands study procedures and is able to comply.
Exclusion criteria A participant who meets any of the following criteria will be excluded from participation:
1. Severe participant non- compliance defined as severe non- adherence to the dialysis procedure and 
accompanying prescriptions, especially frequency and duration of dialysis treatment.
2. Life expectancy <3 months.
3. HDF treatment <90 days before screening.
4. Anticipated living donor kidney transplantation <6 months after screening.
5. Evidence of any other diseases or medical conditions that may interfere with the planned treatment, affect 
participant compliance or place the participant at high risk for treatment- related complications.
6. Participation in any other study will be discussed with and decided by the Executive Board.
7. Unavailable ≥3 months during the study conduct for study visits.
ESKD, end- stage kidney disease; HD, haemodialysis; HDF, haemodiafiltration.




20 21 22 23 24 25 26 27 28 29 30 31*
Treatment time 3.5 hours
  Qb† 300 mL/min 63.0 12.6 13.2 13.9 14.5 15.1 15.8 16.4 17.0 17.6 18.3 18.9 19.5
  Qb 350 mL/min 73.5 14.7 15.4 16.2 16.9 17.6 18.4 19.1 19.8 20.6 21.3 22.1 22.8
  Qb 400 mL/min 84.0 16.8 17.6 18.5 19.3 20.2 21.0 21.8 22.7 23.5 24.4 25.2 26.0
Treatment time 4.0 hours
  Qb 300 mL/min 72.0 14.4 15.1 15.8 16.6 17.3 18.0 18.7 19.4 20.2 20.9 21.6 22.3
  Qb 350 mL/min 84.0 16.8 17.6 18.5 19.3 20.2 21.0 21.8 22.7 23.5 24.4 25.2 26.0
  Qb 400 mL/min 96.0 19.2 20.2 21.1 22.1 23.0 24.0 25.0 25.9 26.9 27.8 28.8 29.8
Treatment time .4.5 hours
  Qb 300 mL/min 81.0 16.2 17.0 17.8 18.6 19.4 20.3 21.1 21.9 22.7 23.5 24.3 25.1
  Qb 350 mL/min 94.5 18.9 19.8 20.8 21.7 22.7 23.6 24.6 25.5 26.5 27.4 28.4 29.3
  Qb 400 mL/min 108.0 21.6 22.7 23.8 24.8 25.9 27.0 28.1 29.2 30.2 31.2 32.4 33.5
This table shows the interaction between session treatment time, blood flow rate through the extra corporeal circuit and ‘filtration 
fraction’. Convection volumes of ≥23 L/session are best achieved by a 4- hour session with a minimum blood flow of 350 mL/min. 
Convection volumes ≥23 L/treatment are marked in green.
Formula: Convection volumes in post- dilution HDF in relation to treatment time.
*Filtration fraction (as a percentage of blood flow: (convective flow rate / blood flow rate)×100).
†Effective blood flow rate (Qb).
‡ BV = blood volume
BV, blood value; FF, filtration fraction.
initially achieved, then steps should be undertaken in an 
effort to achieve the target convection volume which may 
require a stepwise adjustment of dialysis prescription to 
achieve this target over 2–3 weeks (online supplementary 
appendices 1-3 and table 2).25 26 If the target convection 
volume still cannot be reached after these steps, then 
the highest volume possible should be used. Convection 
volume, and reasons why the target could not be reached, 
should be recorded into the electronic study case record 
form (eCRF). Centres are required to check dialysis water 
quality to ensure that all patients dialyse with ultra- pure 
water (online supplementary appendix 4).
The control group will receive high- flux HD using high- 
flux dialysis membranes and ultrapure bicarbonate- based 
dialysis fluid as standard of dialysis care.
Co-interventions
During follow- up, patients might receive (in a non- 
randomised fashion) additional co- interventions, 
including blood pressure modifying medication, 
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Table 3 Schedule of the activities in CONVINCE
Visit Screening Randomisation V1 V2 V3 V4 V5 V6 Vn* EOT
















Visit window in days ±14 days ±14 days ±14 days ±14 days ±14 days ±14 days ±14 days ±14 days
Informed consent X






Vital signs and weight‡ X X X X X X X X X
Height X
Vascular access§ X X X X X X X X X
Laboratory¶ X X X X X
Concomitant medication** X X X X X X X X X
Patient Health 
Assessments††
X X X X X X X X X
Physical performance test X
EQ- 5D- 5L X X X X X X X X X
Questionnaire about 
healthcare use, informal 
care and productivity
X X X X X X X X X
Dialysis specifics‡‡ X X X X X X X X X
Serious adverse events§§ X X X X X X X X X X
Study procedures shown in italic are routine clinical practice procedures. Information from these procedures is expected to be available as part of routine clinical 
practice. If not routinely collected, it should be recorded in the electronic study case record form as non- available data.
*Participants are followed for at least 24 months. That means that for the first patient, the follow- up time will be the enrolment time up to the last patient in (12 
months) plus the follow- up time of the last patient in (24 months). So there will be patients that have visits scheduled at 27 months, 30 months, 33 months and 36 
months.
†Subjects randomised to high- dose HDF can continue the study after higher convection volume of ≥23 L in postdilution mode is reached. The reason for not 
reaching higher convection volume should be recorded.
‡Systolic and diastolic blood pressure and heart rate should be measured once before and after dialysis in a sitting position. The body weight before and after 
dialysis will be measured and reported.
§In case of vascular access (native fistula or graft) the results of vascular access flow assessment should be recorded at least twice a year (if available).
¶The following laboratory values will be recorded (incl. units) before dialysis (if available): haemoglobin, sodium, potassium, calcium, phosphate, creatinine, urea, 
magnesium, parathyroid hormone, C- reactive protein and residual renal function (urine sampling). After dialysis the following laboratory values will be recorded (incl. 
units): urea and creatinine. Single- pool Kt/V urea will be calculated and recorded together with the calculation method.
**The following concomitant medication, including dosage and frequency, will be recorded during screening: Antihypertensives: agents affecting the renin- 
angiotensin system, beta blockers; lipid modifying medication; medication used for diabetes; heparin; erythropoiesis stimulating agents; Iron preparations; drugs for 
treatment of hyperkalaemia; phosphate binders; vitamin D and vitamin D analogues; PTH antagonists. The following concomitant medication, including dosage and 
frequency, will be recorded during all study visits: Drugs for treatment of hyperkalaemia; phosphate binders; vitamin D and vitamin D analogues; PTH antagonists; 
erythropoiesis stimulating agents; medication used to treat SAEs.
††During the Screening visit the Patient Health Assessment Screening should be completed. During all other study visits the Patient Health Assessment quarterly. 
In between the study visits, during the first 12 months of study conduct the Patient Health Assessment Monthly should be completed every month. Questionnaires 
need to be completed within the first hour after the dialyses has started.
‡‡The following dialysis specifics will be recorded for all subjects: type of dialyser, delivered blood flow rate in the extracorporeal circuit, dialysis session time, 
anticoagulation, type vascular access, net ultrafiltration volume (=desired weight loss). Additional dialysis specifics will be recorded for subjects receiving high- dose 
HDF: achieved convection volume, substitution volume and number of treatment sessions not performed as HDF in the previous 3 months.
§§SAEs will be assessed from the signing of the Informed Consent Form until end of the study for the subject. If the subject drops out (eg, due to kidney 
transplantation) he/she will be followed for mortality and morbidity until the end of the study.
EOT, end of treatment; HDF, haemodiafiltration; PTH, parathyroid hormone; SAE, serious adverse event.
medication used for managing co- morbid conditions 
and complications of chronic kidney disease, including 
diabetes, ischaemic heart disease and heart failure, as 
part of usual care. Additionally, erythropoiesis stimu-
lating agents (ESAs), iron preparations, drugs for treat-
ment of hyperkalaemia, phosphate binders, vitamin D 
and vitamin D analogues, parathyroid hormone (PTH) 
antagonists and extracorporeal anticoagulants might be 
applied, as these are considered part of routine clinical 
care.
study procedures
Patient visits start at the time of randomisation, followed 
by monthly visits for the first 12 months and then 3 
monthly from 12 months up to 36 months. After rando-
misation, patients will continue thrice weekly dialysis and 
have regular safety and dialysis efficacy assessments, as 
described in table 3. After initial study entry assessments, 
data will be collected and study specific activities will be 
performed every 3 months until the end of the study, 
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apart from the Patient Health Assessment (PHA) ques-
tionnaire which is to be completed monthly for the first 
12 months of the study.
study measurements
After an initial screening visit to determine subject eligi-
bility, suitable patients will be asked to take part in the 
study and provide written informed consent. Patients who 
fail to meet the study entry criteria will not be rescreened. 
Once entered into the study each participant recruited 
into the study will be given a unique study number. Data 
will be collected during routine clinical practice, including 
year of birth, gender, ethnicity, relevant medical history, 
lifestyle information (smoking, alcohol use, work status 
and use of informal care) concomitant medication and 
current medical conditions, including cause of ESKD and 
date of ESKD diagnosis. In keeping with routine clinical 
practice, pretreatment and post- treatment weight, along 
with systolic and diastolic blood pressure and heart rate, 
will be measured once before, and once after, the dialysis 
session in a sitting position during all visits. Height of the 
participant will be recorded at screening only. Vascular 
access flow assessments should be recorded at least twice 
a year.
During all follow- up visits, information will be collected 
on drugs for treatment of hyperkalaemia, phosphate 
binders, vitamin D and vitamin D analogues, PTH antag-
onists, ESAs and medication used to treat serious adverse 
events. During the screening visit, a physical performance 
test will be taken covering nine tasks to assess multiple 
domains of physical function, simulating activities of daily 
living. The physical performance test will be performed 
by dialysis centre staff or members of the research team.27
laboratory measurements
During the study entry visit, at the 6, 12 and 18- month 
review visits, and end of the trial the following laboratory 
values will be recorded before dialysis: haemoglobin, 
sodium, potassium, calcium, phosphate, creatinine, urea, 
magnesium, PTH, C- reactive protein and residual renal 
function (urine sampling). Local laboratory procedures 
will be followed to perform these measurements. After 
dialysis, urea and creatinine will be recorded. Single- pool 
Kt/V urea will be calculated and recorded together with 
the calculation method. All assessments will be performed 
by a local laboratory and are part of standard assessments 
(ie, routine clinical practice) for dialysis participants. If 
centres do not routinely collect all of the data items, those 
items will then be recorded in the eCRF as not routinely 
collected.
dialysis specific measurements
Information will be collected during screening, 6 
monthly review visit, 12 monthly review visit, 18 monthly 
review visit and at the end of trial visit on type of dial-
yser, blood flow rate through the extracorporeal circuit, 
session time, anticoagulation (type and dosage), type of 
vascular access and net ultrafiltration volume (=sessional 
weight loss). For high- dose HDF patients, we will collect 
data on achieved convection volume, substitution volume 
and the number of treatment sessions not performed as 
high- dose HDF in the previous 3 months.
study outcomes
The primary outcome will be all- cause mortality. 
Secondary outcomes will be cardiovascular events which 
comprise:
 ► Cause specific mortality (at least cardiovascular and 
non- cardiovascular death; others with high frequency 
may be added).
 ► Acute coronary syndrome.
 ► Myocardial infarction (STEMI/NSTEMI).
 ► Unstable angina pectoris.
 ► Congestive heart failure.
 ► Coronary artery bypass graft.
 ► Percutaneous transluminal coronary angioplasty 
and/or stenting.
 ► Transient ischaemic attack.
 ► Cerebral vascular accident.
 ► Therapeutic carotid procedure (endarterectomy 
and/or stenting).
 ► Vascular intervention of peripheral arterial ischaemia 
(revascularisation, percutaneous transluminal angi-
oplasty and/or stenting using physician reporting 
based of standard consensus definitions)28–32 (online 
supplementary appendix 5).
 ► Hospitalisation for infection related causes.32
 ► Any hospitalisation of more than 24 hours.
If a participant drops out (eg, due to kidney transplan-
tation, switching to another dialysis modality or transfer-
ring out of the participating centre), effort will be made 
to collect information on his/her vital status until the end 
of the study follow- up.
Assessment of patient-reported outcomes
To determine whether high- dose HDF improves patients’ 
self- reported outcomes (PROs), patients will be asked 
to complete the PHAs (box 1). These assessments were 
compiled following a construct- based approach. In 
due consideration of international initiatives, such as 
Standardised Outcomes in Nephrology (SONG)33 and 
International Consortium for Health Outcomes Measure-
ments (ICHOM),34 and results of interviews with patients 
and healthcare professionals, we determined domains 
and symptoms most relevant to patients with ESKD. 
Based on these, validated questionnaires covering the 
respective health domains were compiled to the Patient 
Health Assessment sets. The PHA sets vary in coverage 
of included health domains. Whereas the baseline assess-
ment is the most comprehensive, only a subset of domains 
are included in the monthly assessment (box 1).
Most health domains will be assessed by use of PROMIS 
measures35 which are based on modern test theory 
methods. The PROMIS item banks allow to apply custom-
ised short forms as well as computer- adaptive tests, aiming 
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box 1 list of the patient reported outcomes (Pros 
questionnaires in ConVInCE)
Patient health assessments
The Patient Health Assessment Screening (PHA- Screening) is a compre-
hensive instrument to assess key sociodemographic information, study 
targeted information about the medical history, their treatment expecta-
tion and their perceived health status. This assessment will also include 
instruments to evaluate factors which may contribute to the outcome 
prediction model (ie, perceived stress, self- efficacy, social support). 
Instruments included in the initial assessment tools are:
 ► Sociodemographic variables & treatment information.
 ► PROMIS Fatigue 6- item customised short form.
 ► Time to recovery module.
 ► Modified Kidney Disease Quality of Life (KDQOL) symptom checklist.
 ► Health transition items (2 items of the SF-36).
 ► PROMIS Physical Function 4- item short form (part of the PROMIS 
Profile-29).
 ► PROMIS Cognitive Abilities 4- item customised short form.
 ► PROMIS Pain Interference 4- item short form (part of the PROMIS 
Profile-29).
 ► PROMIS Pain Intensity one item (part of the PROMIS Profile-29).
 ► PROMIS Anxiety 4- item short form (part of the PROMIS Profile-29).
 ► PROMIS Depression 4- item short form (part of the PROMIS 
Profile-29).
 ► PROMIS Ability to participate in social roles and activities 4- item 
short form (part of the PROMIS Profile-29).
 ► PROMIS Sleep disturbance 4- item short form (part of the PROMIS 
Profile-29).
 ► Perceived Stress Questionnaire 5- item short form.
 ► PROMIS Self- efficacy 4- item short form.
 ► MOS Social Support Scale 4- item short form.
The Patient Health Assessment Quarterly (PHA- Quarterly) is a compre-
hensive assessment of the participants health status, which includes 
the core instruments of the screening instruments:
 ► PROMIS Fatigue 6- item customised short form.
 ► Time to recovery module.
 ► modified KDQOL symptom checklist.
 ► 2 Health transition items (SF-36)–modified.
 ► PROMIS Physical Function 5- item short form (part of the PROMIS 
Profile-29).
 ► PROMIS Cognitive Abilities 4- item customised short form.
 ► PROMIS Pain Interference 4- item short form (part of the PROMIS 
Profile-29).
 ► PROMIS Pain Intensity 1- item (part of the PROMIS Profile-29).
 ► PROMIS Anxiety 4- item short form (part of the PROMIS Profile-29).
 ► PROMIS Depression 4- item short form (part of the PROMIS 
Profile-29).
 ► PROMIS Ability to participate in social roles and activities 4item 
short form (part of the PROMIS Profile-29).
 ► PROMIS Sleep disturbance 4- item short form (part of the PROMIS 
Profile-29).
The Patient Health Assessment Monthly (PHA- Monthly) will monitor the 
health status monthly with a parsimonious assessment of key health 
domains, including fatigue, physical function, depression, social partic-
ipation and items asking about the recovery time. Instruments included 
for the monthly assessment are:
 ► Modified transition question (SF-36).
 ► PROMIS Physical Function 3- item short form (part of the PROMIS 
Profile-29).
 ► PROMIS Fatigue 3- item short form (part of the PROMIS Profile-29).
Continued
box 1 Continued
 ► Two items time to recovery module.
 ► PROMIS Depression 3item short form (part of the PROMIS Profile-29).
 ► PROMIS Ability to participate in social roles and activities 3- item 
short form (part of the PROMIS Profile-29).
Based on the technical infrastructure and the availability of PROMIS item 
banks in participating countries (availability of translations) computer- 
adaptive tests (CATs) might replace the respective PROMIS short forms.
for higher measurement precision, while reducing 
respondent burden.
In addition, we will apply the SF-12 version 236 to assess 
overall health- related quality of life, and the PHQ-937 to 
assess depression.
The Patient Health Assessment sets will be applied 
at screening (PHA- Screening) and every 3 months 
(PHA- Quarterly). During the first 12 months, patients 
will complete a short assessment (PHA- Monthly) on a 
monthly base in between the scheduled visits.
Cost–utility analysis and budget-impact analysis
The economic evaluation will consist of a cost–utility analysis 
to express efficiency in terms of costs per Quality Adjusted 
Life Year (QALY). Incremental costs and effects of both 
treatments will be compared and Incremental Cost Utility 
Ratios will be estimated. The cost–utility analysis takes a 
societal perspective, implying that healthcare costs, patient 
and family costs and productivity costs are included. Health-
care use of patients in both groups will be monitored in 
the eCRF and via patient questionnaires. Patient and family 
costs, including informal care, and productivity losses are 
collected through patient questionnaires. These question-
naires consists of relevant parts of the institute of Medical 
Technology Assessment (iMTA) Productivity Cost Ques-
tionnaire (iPCQ), to capture productivity losses associated 
with ESKD or its treatment,38 and the iMCQ, for healthcare 
use outside the hospital and for patient and family costs.39 
QALYs will be estimated by use of the EQ- 5D- 5L question-
naire.40 The EQ- 5D- 5L is a questionnaires that covers five 
domains of quality of life (ie, mobility, selfcare, usual activ-
ities, pain/discomfort and anxiety/depression) each with 
five levels of functioning (no problems, some problems, 
moderate problems, severe problems, extreme problems). 
The EQ- 5D- 5L describes 3125 (55) unique health states, 
with associated values to be used for QALY calculations.41 
Based on trial data, probabilistic sensitivity analyses with 
5000 bootstrap replications will be applied to estimate the 
Incremental Cost Effectiveness Ratio (ICER) and to plot 
cost- effectiveness planes and acceptability curves. In addi-
tion to the economic evaluation, budget impact analyses will 
be constructed for the different countries that participate 
in the trial, using country specific perspectives, depending 
on the health system of the country.
Monitoring data and safety
An independent Data and Safety Monitoring Board 
(DSMB), comprising two nephrologists and one 
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biostatistician, has been established to monitor the prog-
ress of the study and ensure that the safety of partici-
pants enrolled in the study is not compromised. Details 
of the composition, meetings, roles, responsibilities and 
processes of the DSMB will be documented in the DSMB 
charter. The independent DSMB will review primary 
outcome and safety data at regular intervals. Reports and 
recommendations (continue, amend or stop the study, 
based on cumulative findings) will be reported to the 
Project Coordinator, who is responsible for informing the 
General Assembly (online supplementary appendix 6).
sample size
The recent meta- analysis suggests a 2.5- year mortality rate 
of 40%14 which is in line with multiple other sources, 
including the United States Renal Data System,42 Dialysis 
Outcomes and Practice Patterns Study43 and the afore-
mentioned Cochrane systematic review.19 We anticipate an 
expected risk reduction of 25%. The sample size calcula-
tion is driven by the assumed target HR, a two- sided type 
1 error of 5% and specification of 90% power. This means 
that for a HR of 0.75, 515 events need to be observed. Given 
the above assumptions on the 2.5- year mortality rate, and 
an estimated average follow- up of approximately 2.5 years, 
an estimated number of participants of 900 (HR 0.75) per 
group will need to be recruited. Thus, the total sample 
size will be 1800 participants to be randomised. We intend 
to recruit 400 from academic and hospital based- dialysis 
centres and 1400 from private dialysis providers.
data analysis
Before the anticipated end of the study a final statistical 
analysis plan will be drafted and agreed on by CONVINCE 
General Assembly. The primary analysis will be according 
to the principle of intention- to- treat using a Cox propor-
tional Hazard regression model to estimate the HR for 
death from any cause adjusting for the major prognostic 
factors. Statistical analyses will be conducted that will 
account for postrandomisation events (such as treatment 
switches and kidney transplants) through causal models 
to arrive at adequate estimates of the difference between 
treatments. Finally, analyses, using interaction terms, 
to identify important subgroups of participants (partic-
ularly suited for high- dose HDF or the reverse) will be 
undertaken. Prespecified subgroup analyses by age (<50, 
50–65, >65 years), sex, residual renal function (<200 mL/
day, 200–1000 mL/day and >1000 mL/day), diabetes, 
cardiovascular disease,26–30 a serum albumin ≤40 g/L, 
vascular access and dialysis vintage (<2 years, 2–5 years 
and >5 years) will be performed for exploratory purposes. 
Assumptions and fits of the statistical models will be evalu-
ated using standard approaches.
The analyses of cause- specific deaths, total cardio-
vascular disease and hospitalisations will be as for the 
primary endpoint. PROs analyses will involve general 
linear models and generalised estimating equations of 
changes since baseline, after a transformation to approx-
imate normality if required. This will be adjusted for the 
major prognostic factors, as for the primary endpoint, 
plus the baseline value of the index variable.
Interim analysis
Two formal interim analyses are planned using the 
Haybittle- Peto stopping criterion,44 45 but subject to the 
opinion of the DSMB. This states that we should stop the 
trial at any interim analysis where the absolute value of 
the estimated treatment effect is bigger than three times 
its SE. Using this criterion, the final analysis can still be 
evaluated at the chosen level of significance (5% two- 
sided), without imposing any important degree of error.
Ethical considerations
The study will be conducted in full conformance with the 
principles of the ‘Declaration of Helsinki’ (64th World 
Medical Association (WMA) General Assembly, Fortaleza, 
Brazil, October 2013)46 or with the laws and regulations of 
the country in which the research is conducted, whichever 
affords the greater protection to the participant. A written 
informed consent will be obtained in accordance with the 
Declaration of Helsinki, laws and regulations, the General 
Data Protection Regulation Data Protection Directive 
(Regulation 2016/679) and local regulations. The Investi-
gator will prepare the informed consent form and provide 
the documents to the independent ethics committees for 
approval.
Patient or public involvement
Patients were not involved in the design and development 
of the protocol. We have informed key stakeholders, 
including international patient associations about our 
study prior to patient enrolment. The findings of our 
study will be discussed with patients, healthcare profes-
sionals, policymakers and the public during the course 
and at the end of our study.
EthICs And dIssEMInAtIon
On the basis of current evidence, the optimal HD modality 
for the management of patients with ESKD remains 
unclear. The CONVINCE study has been designed to 
determine the benefits and harms of high- dose HDF 
versus high- flux HD in people with ESKD. Patient perspec-
tives along with a cost- effectiveness analysis will also be 
performed. The study has potential to deliver an answer 
on the vexing question as to which intervention gives the 
best patient relevant outcomes and is most cost- effective. 
We anticipate CONVINCE to be ‘landmark’ study, leading 
to an expected conclusive ‘end of discussion’ report.
ConVInCE website
https://www. ucl. ac. uk/ convince- hemodiafiltration- dial-
ysis- study/ convince- study.
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